NCT00056589View on ClinicalTrials.gov

Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Congenital Bleeding DisorderCongenital FXIII Deficiency
Interventions
DRUG

catridecacog

Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).

Trial Locations (1)

90027

Novo Nordisk Investigational Site, Los Angeles

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00056589 - Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency | Biotech Hunter | Biotech Hunter